I would pick BCMA directed BsAbs first, treat on label (weekly or q 2 week) to best response and then space out the schedule to q 4 weeks (or even q 8 weeks). Basing this on 6+ years experience of using BsAbs in FIH/PI-III as well in the commercial setting. The way to mitigate infections/AEs will be...

We are fortunate to have so many bispecific antibodies (bsAbs) either being approved or getting closer to it in myeloma. As of August 19, 2023, here's the list I can think of - I am likely missing one, and this list will likely be out of date by this time next year if not earlier: Teclistamab (FD...

There's little reason that I can think of to give these antibodies on different schedules. We will probably find that patients with good response after 1-2 months may need dosing quite infrequently, like every 3 months comes to mind.